Cue Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

• Cue Biopharma Inc CUE.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of two analysts for the quarter was for a loss of 14 cents per share. Wall Street expected results to range from -15 cents to -13 cents per share.

• Revenue rose 11.1% to $2.95 million from a year ago; analysts expected $2.40 million.

• Cue Biopharma Inc's reported EPS for the quarter was a loss of 9 cents​.

• The company reported a quarterly loss of $8.48 million.

• Cue Biopharma Inc shares had risen by 21.9% this quarter and lost 23.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Cue Biopharma Inc is $4.00, about 79.2% above its last closing price of $0.83

This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)